Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ADPT

ADPT - Adaptive Biotechnologies Corp Stock Price, Fair Value and News

4.03USD-0.20 (-4.73%)Market Closed

Market Summary

ADPT
USD4.03-0.20
Market Closed
-4.73%

ADPT Stock Price

View Fullscreen

ADPT RSI Chart

ADPT Valuation

Market Cap

593.9M

Price/Earnings (Trailing)

-2.76

Price/Sales (Trailing)

3.4

Price/Free Cashflow

-4.1

ADPT Price/Sales (Trailing)

ADPT Profitability

Return on Equity

-78.23%

Return on Assets

-34.67%

Free Cashflow Yield

-24.38%

ADPT Fundamentals

ADPT Revenue

Revenue (TTM)

174.5M

Rev. Growth (Yr)

11.23%

Rev. Growth (Qtr)

-8.54%

ADPT Earnings

Earnings (TTM)

-215.1M

Earnings Growth (Yr)

17.66%

Earnings Growth (Qtr)

31.59%

Breaking Down ADPT Revenue

Last 7 days

0.8%

Last 30 days

30.8%

Last 90 days

67.9%

Trailing 12 Months

-47.7%

How does ADPT drawdown profile look like?

ADPT Financial Health

Current Ratio

4.51

Debt/Equity

0.48

Debt/Cashflow

-1.03

ADPT Investor Care

Shares Dilution (1Y)

2.12%

Diluted EPS (TTM)

-1.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024174.5M000
2023184.3M189.6M179.7M170.3M
2022154.5M159.7M168.0M185.3M
2021115.9M133.4M146.6M154.3M
202093.3M92.2M92.4M98.4M
201958.6M69.2M78.1M85.1M
2018044.2M49.9M55.7M
201700038.4M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Adaptive Biotechnologies Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 15, 2024
piskel kyle
acquired
-
-
62,520
chief financial officer
Mar 12, 2024
neupert peter m
acquired
12,600
0.84
15,000
-
Mar 05, 2024
lo francis
sold
-50,439
3.43123
-14,700
chief people officer
Mar 05, 2024
taylor stacy l
sold
-45,962
3.43494
-13,381
svp and general counsel
Mar 05, 2024
rubinstein julie
sold
-135,764
3.47489
-39,070
president
Mar 05, 2024
piskel kyle
sold
-26,503
3.43
-7,727
principal accounting officer
Mar 05, 2024
bobulsky susan
sold
-44,628
3.43537
-12,991
chief commercial officer, mrd
Mar 05, 2024
peterson tycho
sold
-53,168
3.44
-15,456
chief financial officer
Mar 05, 2024
robins chad m
sold
-167,007
3.43121
-48,673
ceo and chairman
Mar 05, 2024
benzeno sharon
sold
-100,994
3.43634
-29,390
chief commercial ofc imm med

1–10 of 50

Which funds bought or sold ADPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
China Universal Asset Management Co., Ltd.
reduced
-37.93
-26,869
62,677
0.01%
Jul 19, 2024
Sumitomo Mitsui Trust Holdings, Inc.
added
11.7
5,149,440
24,976,700
0.02%
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
added
769
43,536
48,479
-%
Jul 18, 2024
Rappaport Reiches Capital Management, LLC
unchanged
-
27,913
246,450
0.07%
Jul 18, 2024
Assenagon Asset Management S.A.
sold off
-100
-2,711,980
-
-%
Jul 17, 2024
BROWN, LISLE/CUMMINGS, INC.
unchanged
-
82.00
724
-%
Jul 16, 2024
Mesirow Financial Investment Management, Inc.
sold off
-100
-60,075
-
-%
Jul 15, 2024
MELFA WEALTH MANAGEMENT, INC.
sold off
-100
-32,421
-
-%
Jul 15, 2024
Pinnacle Bancorp, Inc.
unchanged
-
317
2,795
-%
Jul 12, 2024
Edge Wealth Management LLC
unchanged
-
36,900
325,800
0.07%

1–10 of 49

Are Funds Buying or Selling ADPT?

Are funds buying ADPT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADPT
No. of Funds

Unveiling Adaptive Biotechnologies Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 28, 2024
integrated core strategies (us) llc
5.2%
7,731,846
SC 13G
Feb 14, 2024
viking global investors lp
20.7%
29,993,708
SC 13G/A
Feb 13, 2024
vanguard group inc
8.82%
12,767,684
SC 13G/A
Jan 29, 2024
ark investment management llc
8.85%
12,806,513
SC 13G/A
Jan 26, 2024
blackrock inc.
7.9%
11,421,554
SC 13G
Feb 13, 2023
blackrock inc.
8.7%
12,374,197
SC 13G
Feb 10, 2023
ark investment management llc
6.43%
9,201,245
SC 13G
Feb 09, 2023
vanguard group inc
8.25%
11,794,168
SC 13G/A
Sep 12, 2022
price t rowe associates inc /md/
2.9%
4,081,518
SC 13G/A
Feb 14, 2022
matrix capital management company, lp
8.20%
11,572,590
SC 13G/A

Recent SEC filings of Adaptive Biotechnologies Corp

View All Filings
Date Filed Form Type Document
Jun 11, 2024
8-K
Current Report
May 28, 2024
SC 13G
Major Ownership Report
May 24, 2024
DEFA14A
DEFA14A
May 17, 2024
4
Insider Trading
May 07, 2024
8-K
Current Report
May 07, 2024
10-Q
Quarterly Report
Apr 26, 2024
DEFA14A
DEFA14A
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
ARS
ARS

Peers (Alternatives to Adaptive Biotechnologies Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Adaptive Biotechnologies Corp News

Latest updates
MarketBeat16 Jul 202409:33 am

Adaptive Biotechnologies Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-8.5%41,873,00045,784,00037,919,00048,926,00037,647,00055,198,00047,830,00043,660,00038,620,00037,930,00039,467,00038,505,00038,442,00030,185,00026,299,00020,988,00020,910,00024,209,00026,058,00022,138,00012,666,000
Costs and Expenses-22.4%90,635,000116,852,00088,875,00096,744,00094,840,00094,384,00093,261,00096,162,000101,687,00099,526,00095,792,00088,270,00079,722,00074,424,00063,348,00057,897,00055,530,00048,397,00044,111,00038,243,00032,711,000
  S&GA Expenses1.9%22,319,00021,906,00020,493,00023,872,00022,308,00023,716,00021,513,00024,281,00026,093,00026,696,00024,949,00023,216,00020,604,00018,545,00014,474,00014,332,00014,007,00012,640,0009,099,0008,897,0007,817,000
  R&D Expenses5.2%30,245,00028,746,00028,533,00032,237,00032,601,00031,222,00035,658,00037,037,00037,839,00034,699,00036,072,00037,800,00033,772,00035,831,00030,314,00025,992,00023,935,00021,189,00020,506,00016,527,00012,483,000
EBITDA Margin---------1.19-1.25-1.26---1.07-1.26-0.50-0.50-0.50-0.54---
Interest Expenses-0.6%2,993,0003,012,0003,652,0003,605,0003,531,000-653,000--------------
Income Taxes---------------688,000-1,481,000-323,000----
EBT Margin---------1.30-1.34-1.34---1.26-1.49-0.74-0.74-0.74-0.81---
Net Income31.6%-47,507,000-69,441,000-50,300,000-47,810,000-57,699,000-40,128,000-45,281,000-52,046,000-62,736,000-58,084,500-55,903,000-55,998,000-40,642,000-44,570,000-36,719,000-33,535,000-31,403,000-20,611,000-13,950,000-15,659,000-18,386,000
Net Income Margin6.8%-1.23-1.32-1.09-1.01-1.06-1.08-1.30-1.43-1.51-1.36-1.34-1.33---------
Free Cashflow-41.2%-39,864,000-28,230,000-49,462,000-27,253,000-62,076,000-32,561,000-47,840,000-52,363,000-67,530,000-63,071,000-58,062,000-59,254,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-6.2%6206617187657918578848078589239931,0331,0721,1161,095855875912917601467
  Current Assets-8.8%374410435477501562564439419403467644765727877600585613601442-
    Cash Equivalents9.5%71.0065.0089.0010995.0090.0021876.0011513912218417412349736521397.0075.0048.00-
  Inventory-8.0%13.0014.0019.0019.0020.0014.0017.0019.0021.0019.0018.0019.0017.0014.0011.0011.0011.009.009.008.00-
  Net PPE-4.3%65.0068.0077.0079.0081.0083.0087.0087.0086.0085.0088.0075.0056.0040.0031.0027.0025.0060.0047.0022.00-
  Goodwill0%119119119119119119119119119119119119119119119119119119119119-
Liabilities-2.1%346353356369368393396288305319341340346373320325323341331324177
  Current Liabilities-5.8%83.0088.0093.0095.0090.0011010411111511412211710710510193.0078.0078.0073.0075.00-
  Long Term Debt0.7%132131127--125---------------
    LT Debt, Non Current0.7%132131127--125---------------
Shareholder's Equity-10.9%275308362396424464488518553604652693726743775530552571586--
  Retained Earnings-4.2%-1,191-1,144-1,074-1,024-976-919-878-833-781-718-657-601-552-511-467-430-396-365-344-330-
  Additional Paid-In Capital1.0%1,4671,4531,4371,4221,4031,3871,3731,3581,3401,3241,3091,2951,2771,2541,24195894593693046.00-
Shares Outstanding1.6%147145145145144143143142142140140140---------
Minority Interest-21.5%-0.15-0.12-0.09-0.07-0.07-0.07-0.030.000.000.000.000.000.00--------
Float----756---899---3,951---3,590---2,009-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-42.4%-38,353-26,932-46,684-23,556-59,152-30,019-42,408-47,065-64,453-53,826-43,443-37,213-58,245-39,844-47,156-31,077-31,606-26,791-30,138-15,970278,303
  Share Based Compensation-8.1%14,29815,55615,33617,34514,67114,29414,14214,18012,86111,87511,64311,2498,4847,2436,4706,3734,6753,4293,3003,3323,046
Cashflow From Investing1287.9%44,5093,20726,13837,32362,979-97,54458,0154,74637,68867,212-21,26841,44793,819-340,049-97,246177,492142,75946,680-260,852-45,349-222,176
Cashflow From Financing-49.4%44.0087.0017.001,4696726.00125,5203,9902,7493,2782,9266,32814,6146,253276,0386,3374,9591,746319,550-1,504124
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ADPT Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues [Abstract]  
Revenue$ 41,873$ 37,647
Operating expenses  
Cost of revenue18,05118,681
Research and development30,24532,601
Sales and marketing22,31922,308
General and administrative19,59720,831
Amortization of intangible assets423419
Total operating expenses90,63594,840
Loss from operations(48,762)(57,193)
Interest and other income, net4,2223,024
Interest expense[1](2,993)(3,531)
Net loss(47,533)(57,700)
Add: Net loss attributable to noncontrolling interest261
Net loss attributable to Adaptive Biotechnologies Corporation$ (47,507)$ (57,699)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic$ (0.33)$ (0.40)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic145,787,527143,511,142
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted$ (0.33)$ (0.40)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted145,787,527143,511,142
[1]Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement.

ADPT Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 71,233$ 65,064
Short-term marketable securities (amortized cost of $237,745 and $281,122, respectively)237,639281,337
Accounts receivable, net42,02137,969
Inventory13,29114,448
Prepaid expenses and other current assets9,85011,370
Total current assets374,034410,188
Long-term assets  
Property and equipment, net65,26068,227
Operating lease right-of-use assets50,99952,096
Restricted cash2,9632,932
Intangible assets, net4,7055,128
Goodwill118,972118,972
Other assets3,3903,591
Total assets620,323661,134
Current liabilities  
Accounts payable12,1707,719
Accrued liabilities7,9148,597
Accrued compensation and benefits6,40413,685
Current portion of operating lease liabilities9,5949,384
Current portion of deferred revenue46,87048,630
Total current liabilities82,95288,015
Long-term liabilities  
Operating lease liabilities, less current portion86,90089,388
Deferred revenue, less current portion44,16044,793
Revenue interest liability, net131,545130,660
Total liabilities345,557352,856
Commitments and contingencies (Note 9)
Shareholders’ equity  
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock: $0.0001 par value, 340,000,000 shares authorized at March 31, 2024 and December 31, 2023; 147,368,324 and 145,082,271 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively1414
Additional paid-in capital1,466,8441,452,502
Accumulated other comprehensive (loss) gain(106)215
Accumulated deficit(1,191,839)(1,144,332)
Total Adaptive Biotechnologies Corporation shareholders’ equity274,913308,399
Noncontrolling interest(147)(121)
Total shareholders’ equity274,766308,278
Total liabilities and shareholders’ equity$ 620,323$ 661,134
ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
 CEO
 WEBSITEadaptivebiotech.com
 INDUSTRYBiotechnology
 EMPLOYEES790

Adaptive Biotechnologies Corp Frequently Asked Questions


What is the ticker symbol for Adaptive Biotechnologies Corp? What does ADPT stand for in stocks?

ADPT is the stock ticker symbol of Adaptive Biotechnologies Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adaptive Biotechnologies Corp (ADPT)?

As of Fri Jul 19 2024, market cap of Adaptive Biotechnologies Corp is 593.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADPT stock?

You can check ADPT's fair value in chart for subscribers.

What is the fair value of ADPT stock?

You can check ADPT's fair value in chart for subscribers. The fair value of Adaptive Biotechnologies Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adaptive Biotechnologies Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adaptive Biotechnologies Corp a good stock to buy?

The fair value guage provides a quick view whether ADPT is over valued or under valued. Whether Adaptive Biotechnologies Corp is cheap or expensive depends on the assumptions which impact Adaptive Biotechnologies Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADPT.

What is Adaptive Biotechnologies Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, ADPT's PE ratio (Price to Earnings) is -2.76 and Price to Sales (PS) ratio is 3.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADPT PE ratio will change depending on the future growth rate expectations of investors.